Actinogen Medical (ACW) Price & Analysis

Compare

37 Followers

ACW Stock Chart & Stats

AU$0.04

>-AU$0.01(-3.85%)

At close: Jan 09 4:00 PM EST

AU$0.04

>-AU$0.01(-3.85%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.07

Previous CloseN/A

Volume244.11K

Average Volume (3M)6.03M

Market Cap

AU$150.18M

Enterprise ValueAU$133.29M

Total Cash (Recent Filing)AU$6.53M

Total Debt (Recent Filing)AU$366.31K

Price to Earnings (P/E)―

Beta-0.43

Next Earnings

Sep 02, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding3,575,659,000

10 Day Avg. Volume4,755,726

30 Day Avg. Volume6,028,147

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)3.74

Price to Sales (P/S)12.48

P/FCF Ratio-9.03

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.08

Price Target Upside112.24% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)AU$5.50M

Bulls Say, Bears Say

Bulls Say

Low Leverage And Healthy Equity RatioLow debt and a relatively healthy equity ratio provide structural financial flexibility for a clinical-stage biotech. Limited leverage reduces bankruptcy risk and preserves options to raise capital or pursue partnerships without heavy interest burdens, supporting longer R&D timelines.

High Gross Profit MarginA reported 100% gross margin reflects the business model of a clinical-stage biotech with minimal cost of goods pre-commercialization. If the company achieves regulatory success and commercialisation, product sales could translate into high incremental margins and strong long-term profitability potential.

Focused R&D Pipeline (xanamem Lead Candidate)A clear strategic focus on xanamem and targeting brain cortisol activity gives the company a defined development path in neuropsychiatric and neurodegenerative areas. A concentrated pipeline can streamline resource allocation and, on positive clinical results, create durable competitive advantage in a specialist niche.

Bears Say

Sharp Revenue DeclineA near-40% revenue decline is a durable warning about commercial or grant funding trends and reduces internal funding for R&D. Sustained revenue contraction erodes runway, increases reliance on external financing, and complicates long-term planning for clinical programs and development milestones.

Persistent Negative Margins And LossesDeeply negative net, EBIT and EBITDA margins indicate ongoing structural unprofitability. Over the medium term this necessitates continued capital raises or partnerships, risks shareholder dilution, and constrains the company's ability to reinvest in trials or expand the development portfolio independently.

Negative Operating And Free Cash FlowNegative operating and free cash flow with declining FCF growth undermines financial sustainability. Poor cash generation shortens runway, increases urgency for financing, and raises the risk that development programs could be delayed or scaled back without new capital or strategic partnerships.

Actinogen Medical News

Actinogen Medical Seeks Quotation for Additional ASX Shares

The latest update is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has applied for quotation on...

5d ago

Actinogen Medical Seeks ASX Quotation for Over 113 Million New Shares

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical Limited has applied for quotation...

8d ago

Actinogen secures $16.8m to fund pivotal Alzheimer’s trial

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical has completed a $16.8 million...

11d ago

Actinogen Medical Adds 67,499 New Shares to ASX Quotation

Actinogen Medical ( ($AU:ACW) ) has shared an announcement. Actinogen Medical Limited, an ASX-listed biotechnology company trading under...

12d ago

Actinogen Medical Widens Half-Year Loss as R&D Spending Rises

Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical reported a modest decline in revenue from...

12d ago

Actinogen boosts cash reserves with additional A$1.9m R&D tax rebate

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has received a further A$1.87...

27d ago

Actinogen Medical launches $5m digital-only share purchase plan for retail investors

Actinogen Medical ( ($AU:ACW) ) has provided an update. Actinogen Medical has launched a share purchase plan offering...

28d ago

Actinogen launches discounted share purchase plan to fund Alzheimer’s trial

An announcement from Actinogen Medical ( ($AU:ACW) ) is now available. Actinogen Medical has launched a share purchase...

28d ago

Actinogen Raises Capital via Institutional Share Placement to Support Late-Stage Trials

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has raised capital by issuing...

29d ago

Actinogen Seeks ASX Quotation for 269.8 Million New Shares

The latest announcement is out from Actinogen Medical ( ($AU:ACW) ). Actinogen Medical has applied to the ASX...

29d ago

ACW FAQ

What was Actinogen Medical Limited’s price range in the past 12 months?

Actinogen Medical Limited lowest share price was AU$0.02 and its highest was AU$0.07 in the past 12 months.

What is Actinogen Medical Limited’s market cap?

Actinogen Medical Limited’s market cap is AU$150.18M.

When is Actinogen Medical Limited’s upcoming earnings report date?

Actinogen Medical Limited’s upcoming earnings report date is Sep 02, 2026 which is in 177 days.

How were Actinogen Medical Limited’s earnings last quarter?

Actinogen Medical Limited released its earnings results on Feb 25, 2026. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.

Is Actinogen Medical Limited overvalued?

According to Wall Street analysts Actinogen Medical Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Actinogen Medical Limited pay dividends?

Actinogen Medical Limited does not currently pay dividends.

What is Actinogen Medical Limited’s EPS estimate?

Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Actinogen Medical Limited have?

Actinogen Medical Limited has 3,575,659,000 shares outstanding.

What happened to Actinogen Medical Limited’s price movement after its last earnings report?

Actinogen Medical Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Actinogen Medical Limited?

Currently, no hedge funds are holding shares in AU:ACW

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Actinogen Medical Stock Smart Score

Outperform

Fundamentals

Return on Equity

-75.99%

Trailing 12-Months

Asset Growth

12.72%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Actinogen Medical Limited

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, Alzheimer's disease, depression with cognitive impairment, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Actinogen Medical (ACW) Earnings & Revenues

Historic Earnings Reports

ACW Stock 12 Month Forecast

Average Price Target

AU$0.08

▲(112.24% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.078887300748928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.0848956488,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.078887300748928,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.041,0.04391440774991754,0.04682881549983508,0.04974322324975262,0.052657630999670156,0.055572038749587695,0.058486446499505226,0.061400854249422765,0.0643152619993403,0.06722966974925784,0.07014407749917538,0.07305848524909292,0.07597289299901046,{"y":0.078887300748928,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.041,0.04437658836923077,0.047753176738461536,0.05112976510769231,0.05450635347692308,0.05788294184615385,0.06125953021538462,0.06463611858461538,0.06801270695384615,0.07138929532307692,0.07476588369230769,0.07814247206153846,0.08151906043076923,{"y":0.0848956488,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.041,0.04391440774991754,0.04682881549983508,0.04974322324975262,0.052657630999670156,0.055572038749587695,0.058486446499505226,0.061400854249422765,0.0643152619993403,0.06722966974925784,0.07014407749917538,0.07305848524909292,0.07597289299901046,{"y":0.078887300748928,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.04,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.034,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.027,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.023,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.025,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.028,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.035,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.059,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.061,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.044,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.041,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >